Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

More Progress Still To Be Made On Mental Health
Commenting on the final biennial report from the Mental Health Act Commission released by the Care Quality Commission, Mental Health Network director Steve Shrubb said:
generic viagra online
Language Use Decreases In Young Children And Caregivers When Television Is On, Study Finds
June 1, 2009: In a new study, young children and their adult caregivers uttered fewer vocalizations, used fewer words and engaged in fewer conversations when in the presence of audible television. The population-based study is the first of its kind completed in the home environment, guided by lead researcher Dimitri A. Christakis, MD, MPH, director of the Center for Child Health, Behavior and Development at Seattle Children"s Research Institute and professor of pediatrics at the University of Washington School of Medicine. "Audible Television and Decreased Adult Words, Infant Vocalizations, and Conversational Turns" was published in the June 2009 issue of Archives of Pediatrics & Adolescent Medicine.
News of the day
On Eve Of Healthcare Rallies, Forums: Nurses, Progressive Democrats Seek Stepped Up Action For Real, "Robust" Reform
With action heating up in Washington for enactment of comprehensive healthcare reform, the nation"s largest RN union and professional association joined with progressive Democratic Party activists today in calling for the most "robust" reform of all to repair the nation"s healthcare crisis, by enacting a single-payer system in the form of an expanded and updated Medicare for all.
Medical Devices

UCB's CIMZIA(R) (certolizumab Pegol) Approved By The U.S. FDA For Adult Patients Suffering From Moderate To Severe Rheumatoid Arthritis

UCB announced that the U.S. Food and Drug Administration (FDA) approved Cimzia®, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia® can be dosed at 400 mg initially and at weeks two and four, followed by 200 mg every other week; for maintenance dosing, 400 mg every four weeks can be considered. In clinical trials with Cimzia®, together with methotrexate (MTX), patients experienced a significant reduction in the signs and symptoms of RA at week 24 with some showing clinical responses within one to two weeks, compared with MTX alone. Additionally, radiographic data showed Cimzia®, together with MTX, inhibited progression of joint damage, with a significantly smaller change from baseline in modified Total Sharp Score (TSS) at 24 and 52 weeks of treatment, compared with MTX alone (p CIMZIA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009